Efficacy and Safety of Liposomal Doxorubicin-based Regimen as First-line Chemotherapy on Advanced Gastric Cancer Patients

Jian MA,Quanliang YANG,Yanzhi BI,Xiaoqian LI,Yang LING

DOI: https://doi.org/10.3969/j.issn.2095-1264.2016.02.12

2016-01-01

Abstract:Objective To study on the efficacy and safety of liposomal doxorubicin-based regimen as first-line chemo-therapy on advanced gastric cancer. Methods Twenty-eight patients with advanced gastric cancer but initial treatment were given pegylated liposomal doxorubicin 25 mg·m-2 at d1, oxaliplatin 60 mg·m-2 at d1 and S-1 80 mg·d-1 at d1-14. A circle lasted for 21 days. The response rate and toxicities were evaluated after two cycles. Results Twenty-eight patients were available for evaluation. No case experienced complete remission. There were 15 cases of partial remission, 9 cases of sta-ble disease and 4 cases of progressive disease. The overall response rate was 53.65% (15/28). The median progression-free survival was 8.3 months. Side effects included leucopenia (32.1%), nausea and vomiting (28.6%), thrombocytopenia and so on. Conclusion Pegylated liposomal doxorubicin, oxaliplatin and S-1 as initial treatment had high efficacy and acceptable side effects for advanced gastric cancer patients.